Psoriasis patients taking deucravacitinib (Sotyktu, BMS) once daily sustained results over a three-year period,according to long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials presented at the American Academy of Dermatology’s annual meeting in San Diego, CA.
For the study, patients were randomized 1:2:1 to oral placebo, deucravacitinib 6mg once daily, or apremilast 30mg (Otezla, Amgen) twice daily. At week 52, patients could enroll in the POETYK long-term extension trial and receive open-label deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor.
Efficacy was evaluated in 513 patients who received continuous deucravacitinib from Day 1 of the parent trials for up to three years (week 148) as of the data cutoff (June 15, 2022). Outcomes included mean change from baseline Psoriasis Area and Severity Index (PASI) analyzed using modified baseline observation carried forward, and proportions of patients achieving treat-to-target absolute PASI thresholds.
From a mean baseline PASI score of 21.1, improvements were observed beginning at Week 1 through Week 16 and further improved through Week 52. These improvements were maintained through Week 148. Proportions of patients achieving 75%-80% reduction from baseline in PASI (75<80), 80<85, 85<90, 90<95, and 95<100, treat-to-target absolute PASI thresholds of ≤1, ≤2, ≤3, ≤4, and ≤5, and absolute PASI of >1 to ≤3 and >3 to ≤5 were increased/maintained from Week 16 through Week 52 and subsequently through Week 148, the study showed.
“Efficacy outcomes in PASI scores and at treat-to-target thresholds were clinically meaningful through three years of continuous deucravacitinib treatment, “conclude the researchers who were led by TDD Editorial Advisory Board Member Linda Stein Gold, MD, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health in East Bloomfield, MI.
